Learn

From the moment a pill is swallowed until its effect appears and fades again — pharmacokinetics and pharmacodynamics explained in the language of what a person with Parkinson's disease actually feels.

Why does the same levodopa work quickly one day and slowly the next? Delayed ON, incomplete ON, ON failure, and wearing-off, explained through the body's actual curve.

The narrow therapeutic window between OFF and dyskinesia, peak and trough, and why matching the medication gets harder as the disease progresses — worked out through actual lived experience in the body.

How fast-acting and slow-acting drugs, medication-extending agents, and adjunct drugs combine within a single day's curve — explained through actual bodily experience.

Based on real records from August 29 to September 2, 2026, this installment follows why the same medication produces different results, carefully distinguishing observation from hypothesis.

Delayed ON, incomplete ON, ON failure, wearing-off, and dyskinesia don't show up in a simple ON/OFF record — this is how I began telling them apart by keeping notes.

Looking back at why the same drug doesn't produce the same result, this closing chapter sums up how keeping records and living through the experience taught me to understand pharmacology again.

Why two evenings both logged as ON felt completely different — rethinking partial response and the therapeutic window through an extended-release levodopa and immediate-release 50 mg experience.

The story of a period when raising the dose never made OFF disappear, and how I came to ask instead how long the same total dose could keep me in a livable range. A concept diagram and a real day's record lay out my personal idea of "dopamine efficiency."

Relearning neuroanatomy through Parkinson's disease. Instead of memorizing the names of structures, we start from lived experience and follow the circuits to ask why the body stops — and moves again.

Movement is not made by muscle strength alone. Starting from real Parkinson's experience, this article explains how the motor cortex, basal ganglia, cerebellum, brainstem, and spinal cord create and initiate movement together.

Strength remains — so why is the first step hard, and why do movements shrink? Following the basal ganglia motor circuit of caudate, putamen, globus pallidus, subthalamic nucleus, substantia nigra, and thalamus, starting from real Parkinson's experience.

At the basal ganglia's output, a brake stays on even at baseline. This article explains, in three sentences instead of arrows, how the direct pathway opens the gate for the needed movement, the indirect pathway closes the gate on competing movements, and the hyperdirect pathway applies a sudden brake.

In Parkinson's disease, freezing of gait is not a problem of muscle strength — it is a momentary stall in the circuit that starts walking. This article follows the gait circuit that runs from the basal ganglia through the cortex, thalamus, and brainstem PPN/MLR to the spinal cord, and asks why it stalls at thresholds, turns, and dual tasks, and why an external cue can start the feet moving again.

The cerebellum is not the organ that first creates movement — it is the corrector that compares and adjusts the difference between the movement I intended and the movement that actually occurs. In Parkinson's disease, it becomes an important bypass that compensates for a damaged basal ganglia circuit.

In Parkinson's disease, dyskinesia is not simply caused by too much dopamine. Repeated pulsatile stimulation, altered D1 and glutamatergic signaling, and maladaptive plasticity can reshape the basal ganglia-thalamocortical circuit into a hypersensitive state.

Parkinsonian rest tremor is not simply the result of dopamine deficiency. It can be understood as an abnormal oscillatory network in which unstable basal ganglia activity interacts with the cerebellum, thalamus, and motor cortex.

Parkinson's disease can be explained as beginning with the loss of dopaminergic neurons in the substantia nigra, but the symptoms a patient actually experiences arise from changes across many neural networks — not only the motor circuit, but also the autonomic nervous system, sleep, emotion, cognition, and sensation — making it a body-wide neurological disease.

DBS is not a treatment that replaces dopamine. By stimulating key nodes such as the STN, GPi, and VIM, it retunes abnormal firing patterns and network synchronization in Parkinson's disease.

Parkinson's disease is one specific neurodegenerative disease, while parkinsonism is an umbrella term for the range of diseases and conditions — Parkinson's disease among them — that produce parkinsonian symptoms such as bradykinesia, rigidity, and tremor.

Multiple system atrophy (MSA) is an α-synucleinopathy in which α-synuclein accumulates predominantly in oligodendrocytes, while basal ganglia, autonomic, cerebellar, and brainstem systems can degenerate together.

Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy in which tau accumulates in neurons and glial cells across the midbrain, basal ganglia, brainstem, and frontal networks, producing parkinsonian bradykinesia and rigidity together with early falls, axial rigidity, and vertical eye-movement impairment.

Corticobasal syndrome (CBS) is a clinical syndrome combining markedly asymmetric parkinsonism with cortical features such as apraxia, cortical sensory loss, alien limb phenomena, myoclonus, and language dysfunction. Corticobasal degeneration (CBD), one important underlying pathology, is a 4-repeat tauopathy.

Dementia with Lewy bodies (DLB) is an α-synucleinopathy in which Lewy pathology affects cortical, limbic, attention, perception, sleep, motor, and autonomic networks. Cognitive fluctuations, recurrent visual hallucinations, REM sleep behavior disorder, and parkinsonism are central clinical features, with timing helping distinguish DLB from Parkinson's disease dementia.

The key to distinguishing Parkinson's disease from atypical parkinsonism is not one symptom, but the pattern over time: levodopa response, disease speed, early falls, autonomic dysfunction, eye-movement abnormalities, cerebellar signs, cortical signs, cognitive changes, and hallucinations.